Open AccessNS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety
Author(s) -
И. Г. Бакулин,
В. Д. Пасечников,
Анна Андреевна Варламичева,
Irina Sannikova
Publication year - 2014
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v6.i5.326
Subject(s) - medicine , ribavirin , dosing , protease , protease inhibitor (pharmacology) , pharmacology , adverse effect , pegylated interferon , clinical trial , hepatitis c , safety profile , ns3 , hepatitis c virus , chronic hepatitis , intensive care medicine , virology , virus , viral load , biochemistry , chemistry , antiretroviral therapy , enzyme
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.